An assessment by the Statin Cognitive Safety Task Force: 2014 update

被引:87
作者
Rojas-Fernandez, Carlos H. [1 ,2 ,3 ,4 ]
Goldstein, Larry B. [5 ,6 ]
Levey, Allan I. [7 ]
Taylor, Beth A. [8 ,9 ]
Bittner, Vera [10 ]
机构
[1] Univ Waterloo, Schlegel UW Res Inst Ageing, Kitchener, ON N2G 1C5, Canada
[2] Univ Waterloo, Sch Publ Hlth & Hlth Syst, Kitchener, ON N2G 1C5, Canada
[3] Univ Waterloo, Sch Pharm, Kitchener, ON N2G 1C5, Canada
[4] Univ Waterloo, McMaster Univ, Michael G DeGroote Sch Med, Dept Family Med, Hamilton, ON, Canada
[5] Duke Univ, Duke Stroke Ctr, Durham, NC USA
[6] Durham VAMC, Durham, NC USA
[7] Emory Univ, Dept Neurol, Atlanta, GA 30322 USA
[8] Hartford Hosp, Dept Prevent Cardiol, Hartford, CT 06115 USA
[9] Univ Hartford, Hartford, CT USA
[10] Univ Alabama Birmingham, Div Cardiovasc Dis, Prevent Cardiol Sect, Birmingham, AL 35294 USA
关键词
Statins; Cognition; Memory; Adverse drug effects; Iatrogenesis; COA REDUCTASE INHIBITORS; ISCHEMIC-STROKE; LOWERING AGENTS; SCREENING TOOL; OLDER-ADULTS; MEMORY LOSS; IN-VITRO; IMPAIRMENT; PRAVASTATIN; SIMVASTATIN;
D O I
10.1016/j.jacl.2014.02.013
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The National Lipid Association's Safety Task Force convened a consensus conference of experts to develop a position statement on cognitive function to revise and update that published originally by the Association in the 2006 assessment of statin safety by a panel of neurologists. The current expert panel was charged with addressing the specific issue of potential adverse cognitive effects attributable to statins. Search strategies recently used in systematic reviews were used to identify relevant evidence using keywords and topics via Medline searches from 1966 to December 2013. Manual searches of bibliographies were also conducted. Panel members were asked to use the evidence to formulate answers to a series of questions of relevance to the subject matter. The strength of recommendations and quality of evidence were graded using accepted contemporary definitions and procedures. Recommendations to patients, health professionals, and researchers were put forth by the panel to aid in daily clinical decision making, and in future research endeavors. (C) 2014 National Lipid Association. All rights reserved.
引用
收藏
页码:S5 / S16
页数:12
相关论文
共 84 条
  • [1] Effects of statin use on muscle strength, cognition, and depressive symptoms in older adults
    Agostini, Joseph V.
    Tinetti, Mary E.
    Han, Ling
    McAvay, Gail
    Foody, JoAnne M.
    Concato, John
    [J]. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2007, 55 (03) : 420 - 425
  • [2] Alzheimer's Association, 2013, ALZH DIS FACTS FIG
  • [3] [Anonymous], FDA DRUG SAF COMM IM
  • [4] [Anonymous], 2011, Health, United States, 2010: With special feature on death and dying
  • [5] Statins and Cognitive Functioning in the Elderly: A Population-Based Study
    Benito-Leon, Julian
    Louis, Elan D.
    Vega, Saturio
    Bermejo-Pareja, Felix
    [J]. JOURNAL OF ALZHEIMERS DISEASE, 2010, 21 (01) : 95 - 102
  • [6] Atorvastatin, diabetic dyslipidemia, and cognitive functioning
    Berk-Planken, I
    de Konig, I
    Stolk, R
    Jansen, H
    Hoogerbrugge, N
    [J]. DIABETES CARE, 2002, 25 (07) : 1250 - 1251
  • [7] Statin treatment withdrawal in ischemic stroke -: A controlled randomized study
    Blanco, M.
    Nombela, F.
    Castellanos, M.
    Rodriguez-Yanez, M.
    Garcia-Gil, M.
    Leira, R.
    Lizasoain, I.
    Serena, J.
    Vivancos, J.
    Moro, M. A.
    Davalos, A.
    Castillo, J.
    [J]. NEUROLOGY, 2007, 69 (09) : 904 - 910
  • [8] An assessment of statin safety by neurologists
    Brass, LM
    Alberts, MJ
    Sparks, L
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2006, 97 (8A) : 86C - 88C
  • [9] Assessing the progression of mild cognitive impairment to Alzheimer's disease: current trends and future directions
    Brooks, Larry G.
    Loewenstein, David A.
    [J]. ALZHEIMERS RESEARCH & THERAPY, 2010, 2 (05)
  • [10] Collins R, 2004, LANCET, V363, P757